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MRL/ I mice develop progressive, virulent autoilnmune disease that has many of the features of systemic lupus erythematosus. Prophylactic treatment of MRL/I mice with syngeneic photo inactivated autoimmune splenocytes improves survival and inhibits the fuhninant hyperproliferation of abnormal T cells and the production of high titer anti-DNA antibody invariably found in untreated mice. The proliferation of Thy 1 + splenic T cells was sigllificantly decreased, and prolonged T he MRL/ I mouse model of systemic lupus erythematosus provides an experimental system that permits exploration of the effect ofT -cell directed therapcutic maneuvers on the course of autoimmune disease.
MRL/ I mice develop lymphoid hyperplasia, B-ccll hypcracti vity, autoantibodies, circulating imlllune complexes, depressed serulll complement, thymic cortical atrophy [1, 2] Therapies that ablate T cells can improve some of the parameters Manuscript received M'\rch 2, 1989; accepted for publication August 29, 1989. This study was presemed in part at the National Meeting of the Society for Investigative Dermatology, Washington. D.C., May 1-4, 1986. This study was supported by NIH grants ttCA39700, CA3058, a grant from the Systemic Lupus Erythematosus Foundation, and a grant from the Matheson Foundation.
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Photochcmotherapy has recently bcen demonstrated ro be efficacious in the management of patients with the leukemic phase of the aggressive inducer T-cell malignancy. cutaneous T-cell lymphoma (CTCL) [16] . One mech.nism by which phorochcmorherapy may achieve a beneficial effect in CTCL patients is through induction of an autoregulatory response in the recipient, putarively directed against abnormal T-cell idiotypes expressed on the reinfused lymphocytes. If photochemodlcrapy invokes a host response that regulates abnormal inducer T-cell expansions, this approach could be studied in the MRL/I mouse model where a phenotypically aberrant, benign helper T-cell hyperproliferation promotes the development of autoimmune disease. To test whether reinfusion of phoromodified lymphocytes can altcr the course of a fulminant autoimmune process, recipient mice were exposed to syngeneic autoimmune splenocytes prior to the onset of overt disease when a relatively intact immune system was present. Treated mice were monitored by evaluation of reliable indicators of disease progression, including lymphoid organomegaly. survival, lymphocyte phenotype, and anti-DNA antibody rroducrion. Control groups were untreated or received injecrions 0 unmodified autoimmune cells or lysed phototreated cells to determine if the therapy was contingent on the presence of intact effector ce lls of the autoimmune process. The results obtained demonstrated a marked reduction in lymphoid hyperproliferation, prolonged survival, altered splenic lymphoid populations. and decreased production of anti-DNA antibodies in the recipients of phototreated autoimmune cells. Injection of unmodified cells alone was partially eifeC[ive, while damaged cells had no effect, indicating that intact effectOr cells are required for induction of a response. The onset of autoimmune disease, as measured by these parameters. was sign ificantly delayed in treated mice by preexposure to autoimmune effector cells.
MATERIALS AND METHODS
Mice Because the onset of the disease process is slightly earlier in female MRL/l mice {2], male mice were selected for study to insure an adequate opportunity for therapeutic intervention. Young male MRL/MpJ-lpr/lpr mice were obtained from Jackson Laboracories (Bar Harbor, ME) at 4-6 weeks and used as recipients of photoinactivated auwimmune splenocytcs or age-matched untreated controls. Donor male M RL/I mice were retired breeders received at 17 -2 J weeks. BALB/c mice were used as normal controls and werc received from Jackson Labs at 6-7 weeks.
Cells Spleen cell suspensions were prepared under sterile conditions. Splenocytes were liberated by macerating the spleens in a sterile petri dish with forceps. The cells were washed in Hanks buffered sale solution (HBSS, Gibco Laboratories, Grand Island. NY). and red blood cells were lysed with ammonium chloride (0.83%, in water) at 4°C for 10 min. The cells were washed and resuspended in RPMl 1640 (Gibeo) containing 5% fetal calf serum (FCS) for culmre or phosphate-buffered soline (PBS, Gibeo) for treatment with 8 MOP-UVA. Lymph nodes were obtained from the retroperitoneal area and prepared in a similar fashion. Lymph node size was determined by measuring length and width with a ruler.
8 MOP-UV A Protocol The optimal concentration of 8 MOP (Elder. Bryan. OH) and dose of UVA for inhibition of lymphocyte proliferation was determined by development of a dose-response curve (dora nOt ~resented). A drug level of 100 ng/ml and a light dose of 1 joule U)/cm ofUVA ene rgy were selected to phoroinactiyare the splenocytes.
The autoimmune status of the donor MRL/I mice was confirmed by demonstration of humoral anti-ON A antibody or the presence of overt lymphoid organomegaly. Splenocytes (20-50 X 10 6 /ml) were incubated with 100 ng/ml ofa MOP in PBS at 23'C, for 20 min prior to irradiation with 1 j/cm 2 UVA. The light source consisted of a bank of four black lights (FL40, Sylvania GTE Products. Danvers, MA) emitting broad spectrum UVA energy (320 -400 nm). filtered through a sheet of window glass to remove uva emission. The light dose was calculated after measuremenc with a specrrophotometer (IL700A, International Light, Newburyporc. MA). Previously performed controls included cells exposed to UVA alone or shielded with foil and placed on the irradiation surface 116]. These controls demonstrated that human lymphocytes as well as murine lymphocytes were viable at the time of reinfusion, but died gndually over a 5-d interval in vitro and lost the capacity to respond to mitogens because of crosslinking of their DNA by photoaddition of 8-methoxypsoralen.
After irradiation, the cells were washed. resuspended in PBS at 20 -50 X 10' splenocytes/100 .ul, and injected intravenously into the tail vein of recipient MRL/I mice. The viability of the phototreated cells was 90% or greater as de tennined by trypan blue exclusion. Mice received their first injection at 6 weeks of age. a time point rhat is prior to the initiation of Inost of the features of the autoimmune process {19]. The mice were treated at 2-week intervals until conclusion of the experiment. In some protocols, groups of mice were treated in parallel with autoimmune splenocytes without 8 MOP-UVA inactivation or autoimmune cells that had been rapidly frozen and thawed to induce lysis. These mice received the equivalent number of whole or lysed splenocytes as the 8 MOP-UV A experimental group.
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Radioimmunoassay for Anti-Double Stranded DNA Antibodies A solid phase radioimmunoassay (RIA) was performed using calf thymus DNA (Sigma. Chemical Co., St. Louis. MO) at a concentration of t mg/ml in PBS. The DNA was sonicated for 30 min to obtain small fragments and aliquoted (100 III/well) into the wells of a round bottom micfOriter plate (Flow Laboratories. Rockville. MD). The wells were coated with the DNA solution by rotation on a plate shaker (Dynarech Laboratories. Alexandria, V A) for J It at 23°C. The pbte was air-dried overnight in a laminar flow hood. The details of the RIA assay have been previously described [20] . Calf thymus DNA might comain some degree of singlestranded DNA which could result in some detection of autoantibody to both single-as well as double-stranded DNA. However. the final concentration of DNA in the wells was approximately 50 .ug/well and any single-stranded DNA contamination at this level would represent a minor component of rhe DNA present.
Pbenorypic Analysis Monoclonal antibody analysis was performed to determine the phenotype of splenocytes in treated mice and comrol animals. Spleen cell suspensions were prepared and resuspended in RPMI 1640 containing 0.3% bovine serum albumin (BSA). The al1ti-T-cell monoclonal antibodies used were anti-LYT 1.2. Statistics The weight, size, and cellularity of organs obtained from the groups of mice were analyzed for statistical significance by the standard Student t test. Survival data were analyzed using a z statistic to reject the null hypothesis at the a ' "' "' 0.01 level of significance. Fig 2B) . Mi ce receiving unmodified autoimm une cells (N = 9) also had reduced splenic cellularity (p < 0.01). In the group of 46 mice that received photoinactivated autoimmune cells, only four mice (9%) were judged to be treatment failures based 011 early onset of lymphoid organomegaly. In contrast, 20% of the mice tested in the group receiving cells without inactivation were judged to be treatment failures.
An additional group of mice were recipients of photoinactivated autoimmune cells that had been lysed by freezing and thawing prior to injection (results flor shown). These mice exhibited rapid onset of organomegaly (16-20 weeks) and died at an early age (60% mortalicy by 16 weeks of age), Survival The survival of mice treated with injections of photoinactivated autoimmune splenocyces was compared with the survival of mice [redced with unmodified cells or uncreated controls (Table  I ). The group of mice that received unmodified cells from autoimmune donors demonstrated 50% mortdJity by 20 weeks of age. The 50% mortality level was reached in untreated control mice at 23 weeks of age. This rate of control mortality is similar to that reported in other studies [191. In contrast, twice as many of the recipients of photoinactivated autoimmune splenocytes were alive at 23 weeks of age. The increased survival demonstrated in the recipients of photorreatcd splcnocytes was statistically significant in comparison to the controls (a = 0.01) and was maintained from 23-29 weeks, at which time all of rhe untreated control mice had died. The survival of the phototreated splenocyte group was significantly (a = 0.01) prolonged compared to the recipients of unmodified cells at 23 and 26 weeks. Older mice treated with unmochf1ed autoimmune cells were studied uIltil26 weeks. (Fig 3) . Splenocytes from recipi ents of untrcated autoimm une spl enocy tes and con trol mice were also stud - 
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in th e absolute number of splenic T ce lls but not co th e extent demonstrated in the spleens of mjce treated with photomodified au toimmune cells (p < 0.001). The LVt+ splenocyte population was reduced in che splee ns of mice rece iving photomodi6ed (p < 0.025) or untreated autoimmune splenocytes.
Response to LPS and Con A Splenocytes from mice that had received injections of phocomodified or umreated am oi ml11une cells were studicd at various rime points to determine their capacity to respond CO LPS and Con A in comparison to 2ge-matched linermaces. Uccause the treated mice had substantially fewer T cells than the co ntrol s, the results wc re adjusted to reflect the absolute number of B orT cel ls availab le for stimulation. In Fig 4A , controls. The recipients of unmodified autoimmune cells had an equivalent number ofB cells when compared recantrals (Fig 3) , but these cells responded poorly to LPS in comparison to B cells obtained from control MRL/I and the recipients of photoinactivated cells. Over time, the capacity to respond to LPS was lost in all three groups. In Fig 4B, rhe response to Con A of splenic T cells from all three groups of mice (adjusted to reflect the absolute number ofT cells) is presented. Although the absolute number of T cdls was significantly reduced in the group of mice receiving photoinactiv:lrcd splenocytes (Fig 3) Three groups of mice were evaluated in this study. The recipiems of unmodified autoimmune cells represented a parallel treatmem to the photolllacrivated group. These mice were exposed to rhe rclevam T-cell idiorype on the autoimmune cells at an age when their immune system mighr retain the competence to respond to this abnormal expansion of autoreactive cells. Photoinactivation was demonstrated to enhance the host response to injection of this effector T-cell population.
Analysis of bath lymph nodes and spleens from mice treated with either photoinactivated or unmodificd autoimmune lymphocytes demonstrates that a significam reduction in lymphoid organomegaly can be:Jchicved and maintained by this protocol. Lymphadenopathy has been found to he a reliable indicator of disease activity in the MRL/l mouse [19.21] . Mice treated with unmodified as well as photoinactivated autoimmune splenocytes demonstrated a 50% reduction in lymphadenopathy. This decrease in lymph node size and weight was maintained beyond the normal life span of untreated littermates, in recipients of photoinactivaced cells. Recipients of unmodified cells did not demonstrate decreased splenomegaly ulttil late in their trea. tmenr course, indicating that injection of unmodified cells may be relatively less effective than phototreated cdls.
The survival resules indicate that injection of unmodified autoimmune cells docs nOt prolong survival and may in some animals result in earlier death. In contrast. only 9% of the recipients of photomodified autoimmune cells developed early disease. and the majority of these mice survived significantly longer than the untreated controls. The requirement for intact cdls in this treatment regimen was indicated by the resules of a group of mice that received lysed photoinactivated autoimmune splenocytes. These mice died rapidly with manifestations of aggressive autoimmune disease.
Treatment with photoinactivated autoimmune splenocytes not only decreased lymphoid hypcrproliferation and increased survival bur also prevented the induction of anti-DNA antibodies. The possihility rhat this inhibition of autoantibody production was related to a depletion of rhe abnormal T-cell population found in untreated MRL/I mice [22,23J was supported by phenotypic analysis of the splenic populations of treated mice. No significant difference in the absolute number of B cells was found in the spleens of treated micc in comparison to controls. The T-cell population was significantly reduced in the spleens of treated mice. conlirtning chat this form of therapy is mainly T-cell directed and suggesting that inhibition of T-cell hyperproliferation can primarily or in conjunction with dcpiNion of a relevant B-cell subset result in suppression of autoantibody production. The limited reduction in T cells found in the THE JOURNAL OF INVESTIGATIVE DERMATOLOGY spleens of mICe treated wirh ul1modified autoimmune cells suggests that phoroinactivation significantly enhances the ability of syngeneic cell populations to inhibit the onset of autoimmune disease in these mice.
Mitogen assays of the T -and B-cell compartments of treated mice and controls demonstrated that B cells from treated mice responded to a slightly lesser degree than cOl1trols to lPS stimulation. A significant improvement in the observed T-cell hyporesponsiveness to the mitogen Con A [24,251 was found in tite spleens of mice rreared with photoinactivated autoimmune splenocytes. This increased response was found in the residual T-cell population in treated spleens and may reflect retention of a normal T-cell subset. Alternatively, an autoregulatory T-cell population present in these spleens may have an increased capacity to respond to this mitogen.
These resules demonstrate that a similar degree of resolution of the disease process as that achieved by total lymphoid irradiation.
cyclosposproine A, and monoclonal antibody therapy 111-15.26J
can be achieved through the usc of autoimmune splc:nocyres as an immunogen, rendering the recipient capable of inhibiting the fulminant proliferation of abnormal T-cells. Moreover, therapy with photoinactivated autologous lymphocytes obviates the necessity for introducing cyto[Qxic agents and compromising normal immune status.
The role of psoralen and ultraviolet A light in enhancing the imlllunogeniciry of the i,~ected cells Illay he significant. Injection of cells alone was demonstrated to mediate a somewhat similar effee( but mice treated in this fashion died earlier and did not have reduced splenomegaly until late in the treatment protocol. In addition. no normalization of the response to Con A, which may reflect the retemion of normal lymphoid cells [24,251. was found in the spleens of mice treated with unmodified cells. Unmodified autoimmune cells were expected to mediate a similar effect to phototreated autoimmune cells if the treatment protocol mediated a response directed towards cells expressing an autoreactive T -ccll idiorypc. The addition of psoralen and UVA to the reinfused autoimmune cell population served to enhance the effectiveness of this treatment regimen. The partial effectiveness of the il~ection of unmodified autoimmune splenocytes also suggests that the inhibition of the T-cell hyperplasia in treated mice is nor secondary to effects of un metabolized drug but is dependent on the presence of the intact effector cells. Further support for this comention comes from the cxperiment~ using lysed cells treated with psoralen and UVA, whcre exacerbations of the disease process was noted.
The effect ofbysrander normal lymphocytes as well as dendritic cells and macrophages thar inhabit the spleen has not been studied in these protocols. alrhough their roles may be significant. Previous studies have demonstrated that myeloid cells are relatively resistant ro the effects of 8-methoxypsoralcn and ultraviolet A ligln !t81.
Their comriburion to phototherapy will be the focus of future investigations. In addition. the studies of Andersson et al demonstrated that it was possible to induce specific unresponsiveness to the efTeccor cells mediating skin graft rejection by treating antigen-specific lymphocytes sensitized in vitro with Freund's complete adjuvant prior to injection into syngeneic recipients [27] . The requirement for adjuvant in their experiments may be overcome in our system by the reinfusion of phototreated bystander lymphocytes which gradually die and may release substantial amounts of Iymphokines.
Although the underlying mechanism of this mode of therapy remains to be elucidared, the results indicate that this form of immunomodulation is companble to other rypes of T-cell directed modalities. Studies performed by Cohen et al 128.291 have demonstrated that il~ection of inactivated T-cell clones capable of mediating autoimmune disease results in protection against the subsequent induction of the autoimmune process. In 3. similar fashion, reinfusion of uncloned effector cells 10 young MRL/I mice might pennit the development of an autoregulatory response mounted by a relativciy int:Jct immune system. Because trearment of autoimmune discase with autologous photolllodified lymphocytes is clinically practical, further studies of this form of therapy may be of va lue in
